Celldex Therapeutics Inc (NASDAQ: CLDX) kicked off on Monday, down -5.22% from the previous trading day, before settling in for the closing price of $27.01. Over the past 52 weeks, CLDX has traded in a range of $14.40-$30.50.
A company in the Healthcare sector has jumped its sales by 6.91% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -50.11%. With a float of $64.55 million, this company’s outstanding shares have now reached $66.45 million.
Celldex Therapeutics Inc (CLDX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc is 2.86%, while institutional ownership is 107.35%. The most recent insider transaction that took place on Dec 04 ’25, was worth 121,210. In this transaction SVP & GENERAL COUNSEL of this company sold 4,166 shares at a rate of $29.09, taking the stock ownership to the 30,796 shares. Before that another transaction happened on Dec 04 ’25, when Company’s Officer proposed sale 4,166 for $29.10, making the entire transaction worth $121,210.
Celldex Therapeutics Inc (CLDX) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.71 earnings per share (EPS), higher than consensus estimate (set at -0.71) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -50.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.98% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Take a look at Celldex Therapeutics Inc’s (CLDX) current performance indicators. Last quarter, stock had a quick ratio of 13.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 654.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.38, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -4.50 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.83 million. That was inferior than the volume of 0.89 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.19%.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 51.63%, which indicates a significant increase from 21.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.17 in the past 14 days, which was lower than the 1.24 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.20, while its 200-day Moving Average is $22.93. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $26.76. Second resistance stands at $27.93. The third major resistance level sits at $28.56. If the price goes on to break the first support level at $24.97, it is likely to go to the next support level at $24.34. The third support level lies at $23.17 if the price breaches the second support level.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
The company with the Market Capitalisation of 1.70 billion has total of 66,449K Shares Outstanding. Its annual sales at the moment are 7,020 K in contrast with the sum of -157,860 K annual income. Company’s last quarter sales were recorded 730 K and last quarter income was -56,600 K.
